A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) (NCT07673744)
A Phase 2, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Treatment Following Induction With Efgartigimod Administration in Adults With Myasthenia Gravis
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of this study is to evaluate the efficacy of ublituximab in adult participants with MG responding to treatment with efgartigimod.
Who can join: Review the eligibility criteria below.
Location: TG Therapeutics Investigational Trial Site — Colorado Springs, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- TG Therapeutics Investigational Trial Site — Colorado Springs, Colorado
- TG Therapeutics Investigational Trial Site — Colorado Springs, Colorado
- TG Therapeutics Investigational Trial Site — Clearwater, Florida
- TG Therapeutics Investigational Trial Site — Farmington Hills, Michigan
- TG Therapeutics Investigational Trial Site — New Bern, North Carolina
📞 Contact the Study Coordinator
Phone: (877) 575-8489
Email: clinicalsupport@tgtxinc.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myasthenia Gravis
- Myasthenia Gravis Inebilizumab Trial — Orange, California
- Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis — Phoenix, Arizona
- Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis — Boston, Massachusetts
- Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis — Saint Paul, Minnesota
- A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis — Phoenix, Arizona
Explore by condition: All Myasthenia Gravis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.